JP7374891B2 - 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法 - Google Patents

活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法 Download PDF

Info

Publication number
JP7374891B2
JP7374891B2 JP2020520804A JP2020520804A JP7374891B2 JP 7374891 B2 JP7374891 B2 JP 7374891B2 JP 2020520804 A JP2020520804 A JP 2020520804A JP 2020520804 A JP2020520804 A JP 2020520804A JP 7374891 B2 JP7374891 B2 JP 7374891B2
Authority
JP
Japan
Prior art keywords
activatable
seq
antibody
sequence
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020520804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020537649A (ja
JP2020537649A5 (https=
Inventor
シン，シュエタ
リチャードソン，ジェニファー・ホープ
サーワー，ローラ・パターソン
テレット，ジョナサン・アレクサンダー
モーガン－ラッペ，スーザン・イー
エンリケス，トレイシー
ラルストン，シェリー・エル
リーナ，マービン・ロバート
バーダニャーニ，イラーリア
ボーズ，サハナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2020537649A publication Critical patent/JP2020537649A/ja
Publication of JP2020537649A5 publication Critical patent/JP2020537649A5/ja
Priority to JP2023183034A priority Critical patent/JP2024012366A/ja
Application granted granted Critical
Publication of JP7374891B2 publication Critical patent/JP7374891B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020520804A 2017-10-14 2018-10-12 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法 Active JP7374891B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023183034A JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572467P 2017-10-14 2017-10-14
US62/572,467 2017-10-14
PCT/US2018/055733 WO2019075417A1 (en) 2017-10-14 2018-10-12 CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023183034A Division JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法

Publications (3)

Publication Number Publication Date
JP2020537649A JP2020537649A (ja) 2020-12-24
JP2020537649A5 JP2020537649A5 (https=) 2021-07-26
JP7374891B2 true JP7374891B2 (ja) 2023-11-07

Family

ID=64110112

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520804A Active JP7374891B2 (ja) 2017-10-14 2018-10-12 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法
JP2023183034A Pending JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023183034A Pending JP2024012366A (ja) 2017-10-14 2023-10-25 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法

Country Status (36)

Country Link
US (3) US20190111150A1 (https=)
EP (2) EP3834846A1 (https=)
JP (2) JP7374891B2 (https=)
KR (4) KR102529359B1 (https=)
CN (1) CN111278467B (https=)
AR (1) AR115178A1 (https=)
AU (1) AU2018346969A1 (https=)
BR (1) BR112020007302B1 (https=)
CA (1) CA3077730A1 (https=)
CL (1) CL2020000977A1 (https=)
CO (1) CO2020005685A2 (https=)
CR (1) CR20200206A (https=)
CY (1) CY1123968T1 (https=)
DK (1) DK3691692T3 (https=)
DO (1) DOP2023000150A (https=)
EC (1) ECSP20025198A (https=)
ES (1) ES2864013T3 (https=)
HR (1) HRP20210436T8 (https=)
HU (1) HUE054037T2 (https=)
IL (1) IL273586A (https=)
LT (1) LT3691692T (https=)
MA (1) MA50752B1 (https=)
MD (1) MD3691692T2 (https=)
MX (1) MX2020003723A (https=)
PE (1) PE20210125A1 (https=)
PH (1) PH12020550417A1 (https=)
PL (1) PL3691692T3 (https=)
PT (1) PT3691692T (https=)
RS (1) RS61596B1 (https=)
RU (2) RU2022111211A (https=)
SG (1) SG11202003378WA (https=)
SI (1) SI3691692T1 (https=)
SM (1) SMT202100184T1 (https=)
TW (2) TW202330039A (https=)
UY (1) UY37931A (https=)
WO (1) WO2019075417A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024012366A (ja) * 2017-10-14 2024-01-30 アッヴィ・インコーポレイテッド 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
DK3635009T3 (da) 2017-06-07 2026-03-30 Regeneron Pharma Sammensætninger og fremgangsmåder til internalisering af enzymer
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
CN121754667A (zh) * 2020-04-08 2026-03-31 阿里亚达治疗公司 用于血脑屏障递送的组合物和方法
JP2023521384A (ja) * 2020-04-09 2023-05-24 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能抗体を含む組成物
CN116194470B (zh) * 2020-07-23 2025-10-03 达因疗法公司 肌肉靶向复合物及其用途
US20250332265A1 (en) 2021-11-09 2025-10-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
CN120659627A (zh) * 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025133132A1 (en) * 2023-12-20 2025-06-26 Institut National De La Sante Et De La Recherche Medicale Novel anti-tfr1 (cd71) antibodies for cancer treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179257A2 (en) 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
AU2006284651C1 (en) 2005-08-31 2013-09-12 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
CN101888856B (zh) * 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
AU2010241706B2 (en) * 2009-04-29 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. ERG monoclonal antibodies
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
WO2012104344A1 (en) * 2011-02-01 2012-08-09 Genmab A/S Human antibodies and antibody-drug conjugates against cd74
PL2809683T3 (pl) * 2012-01-31 2019-03-29 Sbi Biotech Co., Ltd. Przeciwciało przeciwko fosfolipazie D4
EP2882844B1 (en) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
CN106237341B (zh) * 2016-07-12 2019-07-30 浙江大学 一种抗体偶联药物及其制备方法和应用
PL3691692T3 (pl) * 2017-10-14 2021-07-19 Abbvie Inc. Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179257A2 (en) 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024012366A (ja) * 2017-10-14 2024-01-30 アッヴィ・インコーポレイテッド 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法

Also Published As

Publication number Publication date
RU2771292C2 (ru) 2022-04-29
RU2020115713A (ru) 2021-11-16
CR20200206A (es) 2021-02-18
RU2022111211A (ru) 2022-05-05
PH12020550417A1 (en) 2021-04-12
MA50752B1 (fr) 2021-03-31
DOP2023000150A (es) 2023-08-31
HRP20210436T8 (hr) 2022-01-07
SMT202100184T1 (it) 2021-05-07
HUE054037T2 (hu) 2021-08-30
RU2020115713A3 (https=) 2022-02-25
PL3691692T3 (pl) 2021-07-19
AR115178A1 (es) 2020-12-09
MX2020003723A (es) 2020-07-22
US20190111150A1 (en) 2019-04-18
KR20230004932A (ko) 2023-01-06
EP3691692B1 (en) 2020-12-30
WO2019075417A1 (en) 2019-04-18
AU2018346969A1 (en) 2020-04-23
CN111278467B (zh) 2024-07-30
SI3691692T1 (sl) 2021-04-30
KR20220045088A (ko) 2022-04-12
RS61596B1 (sr) 2021-04-29
JP2020537649A (ja) 2020-12-24
CY1123968T1 (el) 2022-05-27
JP2024012366A (ja) 2024-01-30
TWI780237B (zh) 2022-10-11
CA3077730A1 (en) 2019-04-18
PT3691692T (pt) 2021-03-29
CN111278467A (zh) 2020-06-12
KR102529359B1 (ko) 2023-05-09
BR112020007302B1 (pt) 2023-01-31
SG11202003378WA (en) 2020-05-28
LT3691692T (lt) 2021-05-10
PE20210125A1 (es) 2021-01-19
MD3691692T2 (ro) 2021-05-31
HRP20210436T1 (hr) 2021-04-30
DK3691692T3 (da) 2021-03-22
TW202330039A (zh) 2023-08-01
IL273586A (en) 2020-05-31
BR112020007302A2 (pt) 2020-09-29
KR102385495B1 (ko) 2022-04-15
CO2020005685A2 (es) 2020-05-15
TW201927815A (zh) 2019-07-16
KR20230070046A (ko) 2023-05-19
EP3691692B8 (en) 2021-05-26
EP3691692A1 (en) 2020-08-12
US20240115724A1 (en) 2024-04-11
US20210145978A1 (en) 2021-05-20
KR20200070324A (ko) 2020-06-17
ES2864013T3 (es) 2021-10-13
ECSP20025198A (es) 2020-06-30
CL2020000977A1 (es) 2020-09-11
UY37931A (es) 2019-04-30
EP3834846A1 (en) 2021-06-16
MA50752A (fr) 2020-08-12

Similar Documents

Publication Publication Date Title
JP7374891B2 (ja) 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法
TWI726879B (zh) 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
JP2022548310A (ja) 抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法
CN110662766A (zh) Cd147抗体、可激活cd147抗体及其制备和使用方法
KR20200058406A (ko) 활성화 가능한 항-cd166 항체 및 이의 사용 방법
JP2018520092A (ja) 抗ＩＴＧａ３抗体、活性化可能抗ＩＴＧａ３抗体、およびその使用方法
JP2018520091A (ja) 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法
HK40025681A (en) Anti-cd71 activatable antibody drug conjugates and methods of use thereof
HK40025681B (en) Anti-cd71 activatable antibody drug conjugates and methods of use thereof
BR112017015468B1 (pt) Polipeptídeos isolados, composição farmacêutica compreendendo-os, uso terapêutico destes, molécula de ácido nucleico isolada, vetor, método para produzir um polipeptídeo isolado e método para fabricar um anticorpo ativável que, em um estado ativado, se liga a um alvo
BR122022003994B1 (pt) Polipeptídeos isolados, composição farmacêutica compreendendo os mesmos, uso terapêutico dos mesmos, molécula de ácido nucleico isolada, vetor, bem como métodos de produzir um polipeptídeo isolado e de fabricar um anticorpo ativável que, em um estado ativado, se liga a um alvo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230926

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231025

R150 Certificate of patent or registration of utility model

Ref document number: 7374891

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150